Literature DB >> 15102657

Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk.

Frank L Meyskens1, Patrick J Farmer, Hoda Anton-Culver.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15102657     DOI： 10.1158/1078-0432.ccr-03-0638

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  15 in total

Review 1.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

2.  Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Peter A Kanetsky; Klaus J Busam; Anne Kricker; Bruce K Armstrong; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Li Luo; Irene Orlow; Anne S Reiner; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; Eloise A Parrish; Honglin Hao; David C Gibbs; Jill S Frank; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2017-08-24       Impact factor: 8.551

3.  High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis.

Authors:  Dimitrios Mougiakakos; Riki Okita; Takashi Ando; Christoph Dürr; Jules Gadiot; Jiro Ichikawa; Robert Zeiser; Christian Blank; C Christian Johansson; Rolf Kiessling
Journal:  J Mol Med (Berl)       Date:  2012-01-17       Impact factor: 4.599

Review 4.  Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer.

Authors:  K Karimi; T H Lindgren; C A Koch; Robert T Brodell
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  Melanoma molecular subtypes: unifying and paradoxical results.

Authors:  Nancy E Thomas; Peter A Kanetsky; Colin B Begg; Kathleen Conway; Marianne Berwick
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

6.  Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Authors:  Andrzej Slominski; Blazej Zbytek; Radomir Slominski
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

7.  Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

Authors:  Victoria R Greene; Marcella M Johnson; Elizabeth A Grimm; Julie A Ellerhorst
Journal:  J Invest Dermatol       Date:  2009-06       Impact factor: 8.551

8.  N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice.

Authors:  Murray A Cotter; Joshua Thomas; Pamela Cassidy; Kyle Robinette; Noah Jenkins; Scott R Florell; Sancy Leachman; Wolfram E Samlowski; Douglas Grossman
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

Review 9.  Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances.

Authors:  Strahil Strashilov; Angel Yordanov
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

10.  Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma.

Authors:  Sun Yang; Frank L Meyskens
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.